DE69528624D1 - Anti-Fas Antikörper gegen rheumatische Krankheiten - Google Patents

Anti-Fas Antikörper gegen rheumatische Krankheiten

Info

Publication number
DE69528624D1
DE69528624D1 DE69528624T DE69528624T DE69528624D1 DE 69528624 D1 DE69528624 D1 DE 69528624D1 DE 69528624 T DE69528624 T DE 69528624T DE 69528624 T DE69528624 T DE 69528624T DE 69528624 D1 DE69528624 D1 DE 69528624D1
Authority
DE
Germany
Prior art keywords
fas
monoclonal antibody
antibodies against
rheumatic diseases
fas antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69528624T
Other languages
English (en)
Other versions
DE69528624T2 (de
Inventor
Kusiki Nishioka
Shin Yoneyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE69528624D1 publication Critical patent/DE69528624D1/de
Publication of DE69528624T2 publication Critical patent/DE69528624T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
DE69528624T 1994-09-27 1995-09-27 Anti-Fas Antikörper gegen rheumatische Krankheiten Expired - Lifetime DE69528624T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP27013494 1994-09-27

Publications (2)

Publication Number Publication Date
DE69528624D1 true DE69528624D1 (de) 2002-11-28
DE69528624T2 DE69528624T2 (de) 2003-06-26

Family

ID=17482032

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69528624T Expired - Lifetime DE69528624T2 (de) 1994-09-27 1995-09-27 Anti-Fas Antikörper gegen rheumatische Krankheiten

Country Status (9)

Country Link
US (1) US6086877A (de)
EP (1) EP0709097B1 (de)
KR (1) KR100371000B1 (de)
AT (1) ATE226447T1 (de)
CA (1) CA2158822C (de)
DE (1) DE69528624T2 (de)
DK (1) DK0709097T3 (de)
ES (1) ES2182860T3 (de)
PT (1) PT709097E (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830469A (en) * 1993-10-14 1998-11-03 Immunex Corporation Fas antagonists and uses thereof
AU736287B2 (en) * 1997-03-21 2001-07-26 Sankyo Company Limited Humanized anti-human Fas antibody
AU4772299A (en) 1998-06-18 2000-01-05 Karolinska Innovations Ab Fas peptides and antibodies for modulating apoptosis
AU761544C (en) * 1999-05-24 2004-02-12 Sankyo Company Limited Medicinal compositions containing anti-Fas antibody
US6787136B1 (en) * 1999-09-03 2004-09-07 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
AU1092602A (en) 2000-10-24 2002-05-06 New Ind Res Organization Genomes participating in rheumatoid arthritis, method of the diagnosis thereof, method of evaluating the onset possibility thereof, diagnostic kit for detectingthem and therapeutic method and remedies for rheumatoid arthritis
US20060104951A1 (en) * 2004-11-16 2006-05-18 Mountz John D Akt and regulation of RA synovial fibroblast apoptosis
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
US10071143B1 (en) 2007-05-03 2018-09-11 The Research Foundation For The State University Of New York Methods for non-surgical treatment of carpal tunnel syndrome
WO2010013498A1 (ja) * 2008-08-01 2010-02-04 学校法人聖マリアンナ医科大学 変形性関節症治療剤又は予防剤
JP5792636B2 (ja) * 2010-01-29 2015-10-14 Ａｘｉｓ株式会社 変形性関節症治療剤を含有する注射剤
CN102811737A (zh) * 2010-01-29 2012-12-05 阿克西斯股份有限公司 骨关节炎治疗及预防药物组合物和上述组合物的制造方法
US8877188B2 (en) 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis
HUE057423T2 (hu) 2012-01-12 2022-05-28 Endo Global Ventures Clostridium histolyticum enzim
WO2014066622A2 (en) 2012-10-24 2014-05-01 The Research Foundation For The State University Of New York Use of collagenase to treat glaucoma
US11097005B2 (en) 2014-12-15 2021-08-24 The Brigham And Women's Hospital, Inc. Use of cadherin-11 antagonists to treat metabolic disorders and/or increase insulin sensitivity
CN115969318A (zh) 2017-03-01 2023-04-18 恩多风投有限公司 用于评估和治疗橘皮组织的装置和方法
AU2018244426A1 (en) 2017-03-28 2019-10-17 Endo Ventures Limited Improved method of producing collagenase

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201712A (ja) * 1982-05-18 1983-11-24 Green Cross Corp:The 脂肪乳剤
JPS6051105A (ja) * 1983-08-30 1985-03-22 Green Cross Corp:The プロスタグランジン脂肪乳剤
JPH02237935A (ja) * 1989-03-10 1990-09-20 Bio Kagaku Kenkyusho:Kk エイズ処置剤
WO1991010448A1 (en) * 1990-01-19 1991-07-25 German Cancer Research Center A cell surface antigen associated with cellular apoptosis
CA2067031C (en) * 1991-04-26 2003-02-18 Shigekazu Nagata Dna coding for human cell surface antigen
EP0603194A4 (de) * 1991-07-05 1994-12-07 Seragen Inc Zum rezeptor des epidermalen wachstumsfaktors zielgesteuerte moleküle zur behandlung entzündlicher arthritis.
AU666577B2 (en) * 1992-08-19 1996-02-15 Otsuka Pharmaceutical Co., Ltd. Apoptosis regulator
CA2174132A1 (en) * 1993-10-14 1995-04-20 Immunex Corporation Fas antagonists and uses thereof
US5830469A (en) * 1993-10-14 1998-11-03 Immunex Corporation Fas antagonists and uses thereof

Also Published As

Publication number Publication date
DE69528624T2 (de) 2003-06-26
ES2182860T3 (es) 2003-03-16
ATE226447T1 (de) 2002-11-15
KR100371000B1 (ko) 2003-07-12
CA2158822A1 (en) 1996-03-28
DK0709097T3 (da) 2003-02-24
CA2158822C (en) 2008-12-23
PT709097E (pt) 2003-03-31
EP0709097A1 (de) 1996-05-01
US6086877A (en) 2000-07-11
KR960010024A (ko) 1996-04-20
EP0709097B1 (de) 2002-10-23

Similar Documents

Publication Publication Date Title
DE69528624D1 (de) Anti-Fas Antikörper gegen rheumatische Krankheiten
Verneuil et al. Interstitial granulomatous dermatitis with cutaneous cords and arthritis: a disorder associated with autoantibodies
Rock et al. The pathogenic effect of IgG4 autoantibodies in endemic pemphigus foliaceus (fogo selvagem)
EP0671920A4 (de) Ein anti-idiotypischer antikörper und seine verwendung in der diagnose und therapie von hiv-verwandten krankheiten.
BR0213846A (pt) métodos de induzir seletivamente a apoptose nas células alvo que expressam dr5, de inibir a proliferação de células alvo que expressam dr5 e de tratar um paciente tendo uma doença inflamatória ou doença autoimune, e, composição
UY28170A1 (es) Preparacion y tratamiento para las enfermedades desmielinizantes y paralisis mediante la aplicacion de agentes remielinizantes.
EA200100224A1 (ru) Комбинированная терапия в-клеточных лимфом, предусматривающая введение антитела против cd20
BR0314038A (pt) Anticorpo humano isolado, método de tratar uma doença mediada com il-1 em um paciente, composição farmacêutica, cadeias pesada e leve, e, método de mapeamento de epitopo de um antìgeno selecionado
LU91556I2 (fr) Anticorps humains reconstitués dirigés contre un récepteur de l'interleukine 6 humaine - TOCILIZUMAB
BR0317376A (pt) Anticorpo humanizado (h14.18) do anticorpo 14.18 do camundongo que se liga a gd2 e sua fusão com il-2
AU2001296507A1 (en) Human anti-cd40 antibodies
CY2007001I1 (el) Φαρμακευτικο σκευασμα για χρηση στη θεραπεια του διαβητη
NO20001238D0 (no) Monoklonalt antistoff som induserer apoptose
BR0113213A (pt) Método para diagnosticar uma doença auto-imune, anticorpo, composição de diagnóstico, e, uso do anticorpo
ATE159300T1 (de) Monoklonale antikörper gegen menschliches ige
DE59608213D1 (de) Arzneimittel zur immuntherapie, enthaltend antikörper, die spezifisch das mhcii-antigen eines zu behandelnden patienten erkennen
WO2003054018A3 (en) Anti-tirc7 antibodies in therapy of inflammatory diseases
ATE457318T1 (de) Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper
Patterson-Fortin et al. Serum sickness-like reaction after the treatment of cellulitis with amoxicillin/clavulanate
BR0116010A (pt) Kit imunoterapêutico para o tratamento de tumores
Kanwar et al. Anti‐desmoglein antibody‐negative paraneoplastic pemphigus successfully treated with rituximab
WO2005058358A3 (en) Use of agents derived from ceacam1 for the treatment of inflammatory diseases
Jha et al. Two cases of adult-onset de novo immunoglobulin A vasculitis with nephritis: post-Covishield (ChAdOx1 nCoV-19; Oxford–Astra Zeneca) vaccination
Cavallasca et al. Multiple avascular necrosis in a patient with systemic lupus erythematosus/systemic sclerosis overlap syndrome
ATE232738T1 (de) Kolostrum enthaltende pharmazeutische zusammensetzungen und deren verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition